Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.37 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | AGXT | P21549 | 2/20 | 0.37 |
| ▸ | CTSB | P07858 | 2/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2573264 | 0.80 | MEN1 (0.57) | MEN1KMT2ATAAR1SIGMAR1NLRP3 | |
| SCHEMBL4867233 | 0.80 | POLB (0.44) | MEN1KMT2A | |
| SCHEMBL521090 | 0.80 | MEN1 (0.73) | MEN1KMT2ATAAR1NLRP3PYCR1 | |
| SCHEMBL2794522 | 0.79 | MEN1 (0.55) | MEN1KMT2ATAAR1SIGMAR1NLRP3 | |
| SCHEMBL13220639 | 0.77 | TAAR1 (0.57) | MEN1KMT2ATAAR1SIGMAR1PYCR1 | |
| SCHEMBL31634435 | 0.74 | TAAR1 (0.46) | MEN1KMT2ATAAR1SIGMAR1PYCR1 | |
| SCHEMBL9557375 | 0.72 | MEN1 (0.39) | MEN1KMT2ATAAR1SIGMAR1IDO1 | |
| SCHEMBL1742271 | 0.71 | TAAR1 (0.50) | MEN1KMT2ATAAR1SIGMAR1IDO1 | |
| SCHEMBL4399626 | 0.70 | TAAR1 (0.74) | TAAR1SIGMAR1IDO1AGXT | |
| SCHEMBL591988 | 0.69 | SIGMAR1 (0.47) | TAAR1SIGMAR1PYCR1IDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150306086-A1 | MODULATING CERTAIN TYROSINE KINASES | TESARO, INC. | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150306086-A1 | MODULATING CERTAIN TYROSINE KINASES | ABL1, LCK, FLT3 | MEN1 2235/4885KMT2A 818/4885TAAR1 3080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.